Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | USP25 | Q9UHP3 | 19/20 | 0.69 |
| ▸ | USP28 | Q96RU2 | 16/20 | 0.69 |
| ▸ | MTOR | P42345 | 1/20 | 0.61 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24256673 | 0.88 | MTOR (0.59) | USP25USP28MTOR | |
| SCHEMBL22644967 | 0.87 | NAMPT (0.56) | USP25USP28MTOR | |
| SCHEMBL22957604 | 0.84 | USP25 (0.81) | USP25USP28 | |
| SCHEMBL24592785 | 0.83 | USP25 (0.84) | USP25USP28 | |
| SCHEMBL28691373 | 0.83 | USP25 (0.79) | USP25USP28 | |
| SCHEMBL22957386 | 0.82 | USP25 (1.00) | USP25USP28 | |
| SCHEMBL22957387 | 0.82 | USP25 (1.00) | USP25USP28 | |
| SCHEMBL24592854 | 0.82 | USP25 (0.79) | USP25USP28 | |
| SCHEMBL29707287 | 0.82 | USP25 (0.79) | USP25USP28 | |
| SCHEMBL22957317 | 0.81 | USP25 (1.00) | USP25USP28 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230365583-A1 | FUSED TRICYCLIC PYRIMIDINE-THIENO-PYRIDINE SMALL MOLECULE INHIBITORS OF UBIQUITIN-SPECIFIC PROTEASE 28 | DANA-FARBER CANCER INSTITUTE, INC. | 2023-11-16 | — | — | US | disclosed |
| US-20230365583-A1 | FUSED TRICYCLIC PYRIMIDINE-THIENO-PYRIDINE SMALL MOLECULE INHIBITORS OF UBIQUITIN-SPECIFIC PROTEASE 28 | DANA-FARBER CANCER INSTITUTE, INC. | 2023-11-16 | — | — | US | disclosed |
| WO-2022035806-A1 | FUSED TRICYCLIC PYRIMIDINE-THIENO-PYRIDINE SMALL MOLECULE INHIBITORS OF UBIQUITIN-SPECIFIC PROTEASE 28 | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2022-02-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230365583-A1 | FUSED TRICYCLIC PYRIMIDINE-THIENO-PYRIDINE SMALL MOLECULE INHIBITORS OF UBIQUITIN-SPECIFIC PROTEASE 28 | USP28, USP30, USP8 | USP25 4/4885USP28 1/4885MTOR 2191/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.